keyword
https://read.qxmd.com/read/38703428/the-long-and-winding-road-to-biomarkers-for-immunotherapy-a-retrospective-analysis-of-samples-from-patients-with-triple-negative-breast-cancer-treated-with-pembrolizumab
#21
JOURNAL ARTICLE
L Buisseret, Y Bareche, D Venet, E Girard, A Gombos, P Emonts, S Majjaj, G Rouas, M Serra, V Debien, E Agostinetto, S Garaud, K Willard-Gallo, D Larsimont, J Stagg, F Rothé, C Sotiriou
BACKGROUND: Immune checkpoint blockade (ICB) in combination with chemotherapy improves outcome of patients with triple-negative breast cancer (TNBC) in metastatic and early settings. The identification of predictive biomarkers able to guide treatment decisions is challenging and currently limited to programmed death-ligand 1 (PD-L1) expression and high tumor mutational burden (TMB) in the advanced setting, with several limitations. MATERIALS AND METHODS: We carried out a retrospective analysis of clinical-pathological and molecular characteristics of tumor samples from 11 patients with advanced TNBC treated with single-agent pembrolizumab participating in two early-phase clinical trials: KEYNOTE-012 and KEYNOTE-086...
May 3, 2024: ESMO Open
https://read.qxmd.com/read/38703351/the-development-of-brain-metastases-in-patients-with-different-therapeutic-strategies-for-metastatic-renal-cell-cancer
#22
JOURNAL ARTICLE
Sophie H A E Derks, Edgar L van der Meer, Arjen Joosse, Maja J A de Jonge, Cleo Slagter, Joost W Schouten, Esther Oomen-de Hoop, Marion Smits, Martin J van den Bent, Joost L M Jongen, Astrid A M van der Veldt
A diagnosis of brain metastasis (BM) significantly affects quality of life in patients with metastatic renal cell cancer (mRCC). Although systemic treatments have shown efficacy in mRCC, active surveillance (AS) is still commonly used in clinical practice. In this single-center cohort study, we assessed the impact of different initial treatment strategies for metastatic RCC (mRCC) on the development of BM. All consecutive patients diagnosed with mRCC between 2011 and 2022 were included at the Erasmus MC Cancer Institute, the Netherlands, and a subgroup of patients with BM was selected...
May 4, 2024: International Journal of Cancer. Journal International du Cancer
https://read.qxmd.com/read/38703287/disparities-in-pi3k-mtor-inhibitor-use-toxicities-and-outcomes-among-patients-with-metastatic-breast-cancer
#23
JOURNAL ARTICLE
Claire Sathe, Melissa K Accordino, David DeStephano, Mansi Shah, Jason D Wright, Dawn L Hershman
PURPOSE: Novel agents such as PI3K and mTOR inhibitors (PI3K/mTORi) have expanded treatment options in metastatic breast cancer (MBC). Nevertheless, mortality rates remain disproportionately high for Black patients and patients with lower socioeconomic status. Furthermore, clinical trials for these novel agents lacked diversity, so their toxicity profile in minority populations is uncertain. METHODS: We conducted a retrospective analysis of EHR-derived data from the Flatiron Health Database for patients with HR+, HER2- MBC...
May 4, 2024: Breast Cancer Research and Treatment
https://read.qxmd.com/read/38703285/everolimus-plus-endocrine-therapy-beyond-cdk4-6-inhibitors-progression-for-hr-%C3%A2-her2-advanced-breast-cancer-a-real-world-evidence-cohort
#24
JOURNAL ARTICLE
Rodrigo Sánchez-Bayona, Alfonso Lopez de Sa, Yolanda Jerez Gilarranz, Ana Sanchez de Torre, Manuel Alva, Isabel Echavarria, Fernando Moreno, Pablo Tolosa, Blanca Herrero Lopez, Alicia de Luna, Laura Lema, Salvador Gamez Casado, Ainhoa Madariaga, Sara López-Tarruella, Luis Manso, Coralia Bueno-Muiño, Jose A Garcia-Saenz, Eva Ciruelos, Miguel Martin
PURPOSE: Everolimus in combination with endocrine therapy (ET) was formerly approved as 2nd-line therapy in HR(+)/HER2(-) advanced breast cancer (aBC) patients (pts) progressing during or after a non-steroidal aromatase inhibitor (NSAI). Since this approval, the treatment landscape of aBC has changed dramatically, particularly with the arrival of CDK 4-6 inhibitors. Endocrine monotherapy after progression to CDK4/6 inhibitors has shown a limited progression-free survival (PFS), below 3 months...
May 4, 2024: Breast Cancer Research and Treatment
https://read.qxmd.com/read/38703250/research-progress-of-immunotherapy-for-advanced-head-and-neck-cancer
#25
REVIEW
Anchi Sun, Zhiwei Xing, Rongrong Lv, Pengyuan Niu, Bao Zhao, Shiyin Ma, Hui Li
Head and neck cancer accounts for about one-fifth of all malignant tumors, and the incidence is increasing year by year. The overall mortality rate was high and the 5-year survival rate was low. At present, the combination of surgery, radiotherapy, and chemotherapy is the main treatment in clinical practice, but the treatment of recurrent or metastatic advanced head and neck cancer is still a challenge. With the rise of immunotherapy, more and more studies on immune checkpoint inhibitors have been conducted...
May 4, 2024: Medical Oncology
https://read.qxmd.com/read/38703240/evaluation-of-the-american-college-of-surgeons-risk-calculator-in-hepatectomy-for-metastatic-colorectal-cancer-in-a-southeast-asian-population
#26
JOURNAL ARTICLE
Ye Xin Koh, Ivan En-Howe Tan, Yun Zhao, Hui Min Chong, Boon Hwee Ang, Hwee Leong Tan, Darren Weiquan Chua, Wei-Liang Loh, Ek Khoon Tan, Jin Yao Teo, Marianne Kit Har Au, Brian Kim Poh Goh
PURPOSE: This study evaluated the accuracy of the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) calculator in predicting outcomes after hepatectomy for colorectal cancer (CRC) liver metastasis in a Southeast Asian population. METHODS: Predicted and actual outcomes were compared for 166 patients undergoing hepatectomy for CRC liver metastasis identified between 2017 and 2022, using receiver operating characteristic curves with area under the curve (AUC) and Brier score...
May 4, 2024: Langenbeck's Archives of Surgery
https://read.qxmd.com/read/38703186/effects-of-concurrent-chemoradiotherapy-with-or-without-endostar-on-the-regression-of-retropharyngeal-lymph-node-and-prognosis-of-patients-with-locally-advanced-nasopharyngeal-carcinoma-a-retrospective-study
#27
JOURNAL ARTICLE
Jun-Mei Song, Ning Mo, Yu-Qing Lv, Lu-Lu Huang, Ya-Jing Wen, Ting Liu, Zhi-Ru Li, Ren-Sheng Wang, Ting-Ting Zhang
BACKGROUND AND PURPOSE: To investigate the effect of combining Endostar with concurrent chemoradiotherapy (ECCRT) compared to concurrent chemoradiotherapy (CCRT) on the regression rate of retropharyngeal lymph nodes (RLNs) and the relationship between regression rate of RLNs and prognosis of patients with locally advanced nasopharyngeal carcinoma (LANPC). METHODS: A total of 122 LANPC patients with RLNs metastasis were included. Metastatic RLNs were delineated both before and after treatment slice by slice on the magnetic resonance images cross-section...
May 4, 2024: Journal of Cancer Research and Clinical Oncology
https://read.qxmd.com/read/38702996/lag-3-recent-developments-in-combinational-therapies-in-cancer
#28
REVIEW
Aude Chavanton, Flavie Mialhe, Jimena Abrey, Alvaro Baeza Garcia, Carmen Garrido
The study of anticancer immune responses and in particular the action of immune checkpoint inhibitors that overcome T cell inhibition has revolutionized metastatic patients' care. Unfortunately, many patients are resistant to these innovative immunotherapies. Over the last decade, several immune checkpoint inhibitors, currently available in the clinic, have been developed, such as anti-PD-1/PD-L1 or anti-CTLA-4. More recently, other immune checkpoints have been characterized, among them lymphocyte activation gene 3 (LAG-3)...
May 4, 2024: Cancer Science
https://read.qxmd.com/read/38702821/head-to-head-comparison-of-68-ga-ga-dota-fapi-04-and-18-f-fdg-pet-ct-for-the-evaluation-of-tonsil-cancer-and-lymph-node-metastases-a-single-centre-retrospective-study
#29
COMPARATIVE STUDY
Mengjing Ji, Guang Ma, Cheng Liu, Bingxin Gu, Xinyue Du, Xiaomin Ou, Xiaoping Xu, Shaoli Song, Zhongyi Yang
BACKGROUND: This study aimed to compare the diagnostic value of [68  Ga]Ga-DOTA-FAPI-04 and [18 F]FDG PET/CT imaging for primary lesions and metastatic lymph nodes in patients with tonsil cancer. METHOD: Twenty-one tonsil cancer patients who underwent [68  Ga]Ga-DOTA-FAPI-04 and [18 F]FDG PET/CT scans within two weeks in our centre were retrospectively enrolled. The maximum standardized uptake value (SUVmax) and tumor-to-background ratio (TBR) of the two tracers were compared by using the Mann‒Whitney U test...
May 3, 2024: Cancer Imaging: the Official Publication of the International Cancer Imaging Society
https://read.qxmd.com/read/38702709/a-mitochondrion-targeted%C3%A2-cyanine-agent-for-nir-ii-fluorescence-guided-surgery-combined-with-intraoperative-photothermal-therapy-to-reduce-prostate-cancer-recurrence
#30
JOURNAL ARTICLE
Chenchen Liu, Zong Chang, Kailei Chen, Qiang Xue, Bingxin Shu, Zhihao Wei, Xuan Zhou, Like Guo, Yuling Zhang, Yingying Pan, Qi Cao, Huageng Liang, Qinchao Sun, Xiaoping Zhang
Poorly identified tumor boundaries and nontargeted therapies lead to the high recurrence rates and poor quality of life of prostate cancer patients. Near-infrared-II (NIR-II) fluorescence imaging provides certain advantages, including high resolution and the sensitive detection of tumor boundaries. Herein, a cyanine agent (CY7-4) with significantly greater tumor affinity and blood circulation time than indocyanine green was screened. By binding albumin, the absorbance of CY7-4 in an aqueous solution showed no effects from aggregation, with a peak absorbance at 830 nm and a strong fluorescence emission tail beyond 1000 nm...
May 3, 2024: Journal of Nanobiotechnology
https://read.qxmd.com/read/38702629/radiation-induced-upregulation-of-fgl1-promotes-esophageal-squamous-cell-carcinoma-metastasis-via-impdh1
#31
JOURNAL ARTICLE
Shan Huang, Jiayi Zhang, Pu He, Xinyue Cui, Yuzhu Hou, Wanghui Su, Fang Li
BACKGROUND: While radiation therapy remains pivotal in esophageal squamous cell carcinoma (ESCC) treatment, the perplexing phenomenon of post-radiation metastasis presents a formidable clinical challenge. This study investigates the role of fibrinogen-like protein 1 (FGL1) in driving ESCC metastasis following radiation exposure. METHODS: FGL1 expression in post-radiation ESCC cells was meticulously examined using qRT-PCR, western blotting, and immunofluorescence...
May 3, 2024: BMC Cancer
https://read.qxmd.com/read/38702585/racialized-economic-segregation-and-inequities-in-treatment-initiation-and-survival-among-patients-with-metastatic-breast-cancer
#32
JOURNAL ARTICLE
Harlan Pittell, Gregory S Calip, Amy Pierre, Cleo A Ryals, Jenny S Guadamuz
PURPOSE: Racialized economic segregation, a form of structural racism, may drive persistent inequities among patients with breast cancer. We examined whether a composite area-level index of racialized economic segregation was associated with real-world treatment and survival in metastatic breast cancer (mBC). METHODS: We conducted a retrospective cohort study among adult women with mBC using a US nationwide electronic health record-derived de-identified database (2011-2022)...
May 3, 2024: Breast Cancer Research and Treatment
https://read.qxmd.com/read/38702555/pilot-randomized-controlled-trial-of-a-program-to-enhance-experience-and-adherence-with-adjuvant-endocrine-therapy-among-women-with-non-metastatic-breast-cancer-12-month-quantitative-results
#33
JOURNAL ARTICLE
Odilon Assan, Victoria Memoli, Laurence Guillaumie, Véronique Turcotte, Martine Lemay, Anne Dionne, Julie Lemieux, Louise Provencher, Carolyn Gotay, Marijn de Bruin, Line Guénette, Sophie Lauzier
PURPOSE: Adjuvant endocrine therapy (AET) reduces recurrence risk after hormone receptor-positive breast cancer, but non-adherence is common. We pilot-tested SOIE, a program to enhance AET experience and adherence, to assess its acceptability, feasibility, and effects on psychosocial precursors of AET adherence. METHODS: We conducted a 12-month pilot randomized controlled trial among women who had a first AET prescription. Intervention group received SOIE while control group received usual care...
May 4, 2024: Journal of Cancer Survivorship: Research and Practice
https://read.qxmd.com/read/38702412/extracellular-vesicles-from-aggregatibacter-actinomycetemcomitans-exhibit-potential-antitumorigenic-effects-in-oral-cancer-a-comparative-in-vitro-study
#34
COMPARATIVE STUDY
Marjut Metsäniitty, Shrabon Hasnat, Carina Öhman, Tuula Salo, Kari K Eklund, Jan Oscarsson, Abdelhakim Salem
Aggregatibacter actinomycetemcomitans is an opportunistic Gram-negative periodontopathogen strongly associated with periodontitis and infective endocarditis. Recent evidence suggests that periodontopathogens can influence the initiation and progression of oral squamous cell carcinoma (OSCC). Herein we aimed to investigate the effect of A. actinomycetemcomitans-derived extracellular vesicles (EVs) on OSCC cell behavior compared with EVs from periodontopathogens known to associate with carcinogenesis. EVs were isolated from: A...
May 3, 2024: Archives of Microbiology
https://read.qxmd.com/read/38702396/the-evolving-treatment-landscape-of-metastatic-urothelial-cancer
#35
REVIEW
Giandomenico Roviello, Matteo Santoni, Guru P Sonpavde, Martina Catalano
Cisplatin-based chemotherapy is currently the first-line standard of care for patients with metastatic urothelial cancer (mUC); however, up to 50% of patients are ineligible for cisplatin, necessitating alternative treatment options. Immune checkpoint inhibitors have been shown to be effective in cisplatin-ineligible patients. However, despite advances in the first-line setting, the prognosis remains poor, and challenges persist in selecting optimal therapies, treatment sequences and combination regimens. Maintenance therapy with avelumab revealed improved overall (OS) and progression-free survival (PFS) compared with best supportive care alone in patients with platinum-responsive mUC...
May 3, 2024: Nature Reviews. Urology
https://read.qxmd.com/read/38702214/deep-learning-radiomics-model-of-contrast-enhanced-ct-for-differentiating-the-primary-source-of-liver-metastases
#36
JOURNAL ARTICLE
Wenjing Jia, Fuyan Li, Yi Cui, Yong Wang, Zhengjun Dai, Qingqing Yan, Xinhui Liu, Yuting Li, Huan Chang, Qingshi Zeng
RATIONALE AND OBJECTIVES: To develop and validate a deep learning radiomics (DLR) model based on contrast-enhanced computed tomography (CT) to identify the primary source of liver metastases. MATERIALS AND METHODS: In total, 657 liver metastatic lesions, including breast cancer (BC), lung cancer (LC), colorectal cancer (CRC), gastric cancer (GC), and pancreatic cancer (PC), from 428 patients were collected at three clinical centers from January 2018 to October 2023 series...
May 2, 2024: Academic Radiology
https://read.qxmd.com/read/38702166/the-missing-trial-variable-a-case-report-on-dietary-modification-in-a-patient-with-durable-complete-remission-after-an-immunotherapy-clinical-trial-for-metastatic-bladder-cancer
#37
JOURNAL ARTICLE
Linda L Isaacs, Nicholas J Gonzalez
A patient with metastatic bladder cancer has had an ongoing 9-year complete remission on a clinical trial of immunotherapy with nivolumab and ipimumab, but he also was following an intensive dietary and nutritional supplement regimen. Whether this combination or the immunotherapy alone brought about his good outcome is unknown but could be clarified in future trials by improved data collection about dietary and supplement choices.
May 3, 2024: Alternative Therapies in Health and Medicine
https://read.qxmd.com/read/38702129/sclerosing-mesenteritis-a-concise-clinical-review-for-clinicians
#38
REVIEW
Bibek Saha, June Tome, Xiao Jing Wang
Sclerosing mesenteritis (SM), an idiopathic nonneoplastic condition affecting 0.18% to 3.14% of the population, is characterized by chronic fat necrosis, inflammation, and fibrosis most commonly of the mesentery of the small intestine. Sclerosing mesenteritis typically presents in the fifth or sixth decade of life, where patients with a history of abdominal surgery and/or autoimmune disease may be at higher risk. While many patients are asymptomatic, clinical features and complications are related to the mass effect resulting from the inflammation and fibrosis involved in the pathogenesis of SM...
May 2024: Mayo Clinic Proceedings
https://read.qxmd.com/read/38701808/laryngeal-and-oropharyngeal-adenocarcinoma-with-pulmonary-metastases-in-a-common-raven-corvus-corax
#39
JOURNAL ARTICLE
Katharina M Westhoff, Dominik Fischer, Kathrin Jäger, Katja Trinkaus, Ute Ziegler, Michael Lierz
A captive 15-year-old male common raven ( Corvus corax ) was presented for post-mortem examination. It had been previously presented to a local veterinarian due to a 3-4 weeks long history of abnormal respiratory sounds. Upon admission, the bird demonstrated severe dyspnea and a massive amount of mucous in the oropharynx. After symptomatic treatment, dyspnea deteriorated dramatically, and euthanasia was elicited because of poor prognosis. The necropsy revealed a 2.65 x 2.15 x 2.18 cm expansile and poorly delineated cauliflower-shaped mass around the glottis and extending inside the tracheal lumen...
April 2024: Tierärztliche Praxis. Ausgabe K, Kleintiere/Heimtiere
https://read.qxmd.com/read/38701686/electrospun-nanofibrous-scaffolds-as-a-platform-to-reduce-melanoma-tumour-growth-recurrence-and-promote-post-resection-wound-repair
#40
JOURNAL ARTICLE
Nowsheen Goonoo, Fanny Gimié, Imade Ait-Arsa, Melanie Ziman, Samson A Adeyemi, Philemon Ubanako, Lindokuhle M Ngema, Yahya E Choonara, Archana Bhaw-Luximon
Wound healing following skin tumour surgery still remains a major challenge. To address this issue, polysaccharide-loaded nanofibrous mats have been engineered as skin patches on the wound site to improve wound healing while simultaneously eliminating residual cancer cells which may cause cancer relapse. The marine derived polysaccharides kappa-carrageenan (KCG) and fucoidan (FUC) were blended with polydioxanone (PDX) nanofibers due to their inherent anti-cancer activity conferred by the sulphate groups as well as their immunomodulatory properties which can reduce inflammation resulting in accelerated wound healing...
April 28, 2024: Biomater Adv
keyword
keyword
36941
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.